LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Purchased by Cetera Investment Advisers

Key Points

• Cetera Investment Advisers increased its holdings in LeMaitre Vascular, Inc. by 209.6% in Q1, resulting in ownership of 8,522 shares valued at $715,000.
• LeMaitre Vascular reported $0.60 earnings per share for the last quarter, surpassing estimates by $0.03, with a revenue increase of 15% year-over-year.
• The company declared a quarterly dividend of $0.20, representing an annualized yield of 0.8%, and has a current dividend payout ratio of 38.83%.

Cetera Investment Advisers boosted its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 209.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,522 shares of the medical instruments supplier's stock after acquiring an additional 5,769 shares during the quarter. Cetera Investment Advisers' holdings in LeMaitre Vascular were worth $715,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Raymond James Financial Inc. bought a new position in LeMaitre Vascular during the 4th quarter worth about $14,900,000. Rockefeller Capital Management L.P. bought a new position in LeMaitre Vascular during the 4th quarter worth about $7,787,000. Invesco Ltd. grew its holdings in LeMaitre Vascular by 50.5% during the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after acquiring an additional 58,720 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of LeMaitre Vascular by 7,486.5% during the 1st quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier's stock worth $4,519,000 after purchasing an additional 53,154 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of LeMaitre Vascular by 96.8% during the 4th quarter. Millennium Management LLC now owns 96,081 shares of the medical instruments supplier's stock worth $8,853,000 after purchasing an additional 47,250 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

LeMaitre Vascular Stock Up 0.1%

LeMaitre Vascular stock traded up $0.10 during midday trading on Friday, reaching $95.91. The company's stock had a trading volume of 270,698 shares, compared to its average volume of 164,133. The stock's 50-day simple moving average is $84.56 and its 200-day simple moving average is $86.44. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58. The stock has a market capitalization of $2.17 billion, a P/E ratio of 46.56, a PEG ratio of 2.47 and a beta of 0.79.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 EPS for the quarter, beating analysts' consensus estimates of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.67% and a net margin of 20.08%. The company had revenue of $63.15 million during the quarter, compared to analysts' expectations of $62.48 million. During the same period last year, the business posted $0.52 earnings per share. The firm's revenue was up 15.0% compared to the same quarter last year. On average, sell-side analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st will be issued a $0.20 dividend. The ex-dividend date of this dividend is Thursday, August 21st. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. LeMaitre Vascular's dividend payout ratio is currently 38.83%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on LMAT shares. Barrington Research upgraded LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective for the company in a research note on Wednesday, August 6th. Cantor Fitzgerald upped their price objective on LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 6th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $98.00.

Insider Transactions at LeMaitre Vascular

In other news, Director John A. Roush sold 6,561 shares of the stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $92.55, for a total value of $607,220.55. Following the transaction, the director directly owned 2,916 shares of the company's stock, valued at approximately $269,875.80. This represents a 69.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bridget A. Ross sold 2,500 shares of the stock in a transaction dated Friday, August 8th. The shares were sold at an average price of $94.00, for a total value of $235,000.00. Following the completion of the transaction, the director directly owned 2,916 shares in the company, valued at $274,104. This represents a 46.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 202,082 shares of company stock valued at $18,249,066 over the last three months. Company insiders own 9.50% of the company's stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.